1999
DOI: 10.1086/302235
|View full text |Cite
|
Sign up to set email alerts
|

A Novel 22q11.2 Microdeletion in DiGeorge Syndrome

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

5
95
0
1

Year Published

1999
1999
2014
2014

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 96 publications
(101 citation statements)
references
References 56 publications
5
95
0
1
Order By: Relevance
“…DD and/or ID have been reported in more than 80% of distal 22q11.2 microdeletion patients described in the literature to date and tend to be relatively mild to moderate in severity. [7][8][9][10][11][12][13][14][15][16][17][18] Taken together, global DD and ID seem to be key components of the distal 22q11.2 microdeletions phenotype irrespective of the size and position of the deletion. Behavioral and neurological problems were also quite common in our patients in all deletion types.…”
Section: Discussionmentioning
confidence: 92%
See 3 more Smart Citations
“…DD and/or ID have been reported in more than 80% of distal 22q11.2 microdeletion patients described in the literature to date and tend to be relatively mild to moderate in severity. [7][8][9][10][11][12][13][14][15][16][17][18] Taken together, global DD and ID seem to be key components of the distal 22q11.2 microdeletions phenotype irrespective of the size and position of the deletion. Behavioral and neurological problems were also quite common in our patients in all deletion types.…”
Section: Discussionmentioning
confidence: 92%
“…[7][8][9][10][11][12][13][14][15][16][17][18] These deletions are mediated by nonallelic homologous recombination between the five telomeric LCR22s (LCR22-D to -H) in the distal portion of the 22q11.2 region (Figure 2). 10 Distal 22q11.2 microdeletions that span the LCR22-F to -G interval encompassing the tumor suppressor SMARCB1 gene (also called INI1) have been reported to manifest many of the presenting features mentioned above but also have high incidence of malignant rhabdoid tumors in infancy and early childhood, predominantly in the kidneys and central nervous system, which necessitates tumor surveillance in these patients.…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…5 However, a number of patients with non-overlapping deletions and similar phenotype excludes this model as the pathogenic mechanism. [6][7][8][9] Molecular studies have defined at least four minimum critical regions, the deletion of which results in the DGS/VCFS phenotype. 8,9 The first small region of overlap (SRO1), about 300 Kb in size, was defined by molecular analysis of patients carrying rare rearrangements, including the translocation between chromosomes 2 and 22 (ADU), associated either with DGS or VCFS phenotypes.…”
Section: Introductionmentioning
confidence: 99%